• Skip to primary navigation
  • Skip to main content
  • FortiVac
  • Uses
  • Publications & Patents
Multimeric Biotherapeutics

Multimeric Biotherapeutics

FortiVac Vaccine Platform Technology

  • News & Events
  • About Us
  • Contact

multibio_admin

Multimeric Biotherapeutics to Present at Keystone Symposium on Innovative Vaccine Approaches

June 17, 2021 | Events

SAN DIEGO, CA , June 17, 2021 – Multimeric Biotherapeutics, Inc., a biotechnology company developing vaccines against cancer and infectious diseases, announced today that it has been accepted to present at the Keystone Symposium on Innovative Vaccine Approaches. The meeting will be held as a virtual web conference scheduled June 28-30, 2021.

Continue Reading

Multimeric Biotherapeutics, Inc. Announces Issuance of Second Key US Vaccine Patent for FortiVacTM – a Vaccine Design That Elicits Strong CD8+ T Cell Responses for Anti-Viral Immunity and Tumor Immunotherapy

September 15, 2020 | News

SAN DIEGO, CA, Sept. 15, 2020 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 10/774/149 B2, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.

Continue Reading

Multimeric Biotherapeutics, Inc. Announces Issuance of a European Patent for FortiVac™ – a Vaccine Design That Elicits Strong CD8+ T Cell Responses for Anti-Viral Immunity and Tumor Immunotherapy

December 25, 2019 | News

SAN DIEGO, CA, Dec. 25, 2019 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the European Patent Office (EPO) has issued Patent No. EP 2 970 427 B1, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.

Continue Reading

Multimeric Biotherapeutics to Present at Immunology 2019 Meeting

March 5, 2019 | Events

SAN DIEGO, CA , March 5, 2019 – Multimeric Biotherapeutics, Inc., a biotechnology company developing vaccines against cancer and infectious diseases, announced today that it has been accepted to present at the Immunology 2019 meeting to be held in San Diego, CA. The title of the Company’s abstract is “CD40 ligand (CD40L) multi- trimer antigen fusion protein (FortiVacTM) as a vaccine design for high-level CD8+ T cell responses.”

Continue Reading

Multimeric Biotherapeutics, Inc. Announces Issuance of Key US Patent for FortiVacTM – a Vaccine Design That Elicits Strong CD8+ T Cell Responses for Anti-Viral Immunity and Tumor Immunotherapy

September 11, 2018 | News

SAN DIEGO, CA, Sept. 11, 2018 – Multimeric Biotherapeutics, Inc. (“Multimeric” or the “Company”), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 10,072,064, entitled “Composition Comprised of Antigen Linked to a TNF Superfamily Ligand.” Joint inventors are Geoffrey W. Stone and Richard S. Kornbluth.

Continue Reading

2025 © Multimeric Biotherapeutics, Inc. All rights reserved.